Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — clinical trials in Netherlands
17 open options
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE1RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
RO7812653 · Placebo — 12 sites
- TRIALNARECRUITING
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Plasma p-tau217 and neurofilament light chain results — 8 sites
- TRIALNARECRUITING
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
repetitive transcranial magnetic stimulation · sham repetitive transcranial magnetic stimulation — 1 site
- TRIALNAENROLLING_BY_INVITATION
App-based Protein Support for Older Adults; Coaching Towards Healthy Ageing
Nutritional coaching via an app · Exercise recommendations — 1 site
- TRIALPHASE1RECRUITING
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
ALN-5288 · Placebo — 13 sites
- TRIALNANOT_YET_RECRUITING
Physical Exercise to Prevent Mild-cognitive Impairment in Patients With Kidney Disfunctions
Exercise · Control (Standard treatment) — 6 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
DNL628 · Placebo — 4 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT · KarX-EC · Placebo — 126 sites
- TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
- TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
- TRIALEARLY_PHASE1RECRUITING
[18F]ACI-19626 PET in TDP-43 Proteinopathies
[18F]ACI-19626 — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
ALN-APP · Placebo — 8 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.